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Although great progress has been achieved in the fight against HIV and AIDS, an epidemic continues to 
rage worldwide. Alongside public health and clinical efforts, scientific research plays a major role in this 
fight; ongoing studies focus on improving treatment options, designing a vaccine, and developing a 
cure. The first study described in this dissertation is a critique of research and analysis methods 
commonly used to characterize the latent HIV reservoir, which is considered a barrier to the cure of HIV 
infection. This project highlights the importance of understanding molecular biology tools and 
considering their inherent limitations when interpreting results. The second study presented here 
comprises a quantitative evaluation of the efficacy of dolutegravir, an antiretroviral drug that has 
emerged recently as one of our best weapons for controlling HIV infection. Results show that the high 
efficacy of dolutegravir in combination with other antiretroviral drugs, as well as the high genetic 
barrier to viral evolution of dolutegravir resistance, are consistent with the tremendous clinical success 
of this drug. The grand conclusion of this dissertation is that much work remains to be done. We 
continue to discover safer, more effective tools for the treatment of HIV infection, which may be seen as 
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“It even was suggested that the production of a suitable number of bricks was 
equivalent to building an edifice and therefore should entitle the industrious brickmaker 
to assume the title of builder and, with the title, the authority...And, saddest of all, 
sometimes no effort was made even to maintain the distinction between a pile of bricks 
and a true edifice.” 
 
Bernard K Forscher 







The chapters of this dissertation comprise manuscripts prepared for publication. They are self-
contained, and each includes introduction and discussion sections to contextualize and interpret the 
data presented. For the broader, dissertation-level introduction and discussion sections required by my 
department, I have presented a bird’s-eye view of HIV research from my own perspective, informed by 
the five years I spent in the field. These sections are written in a style somewhere between opinion 
article and memoir. 
 
The opinions presented here represent only my own; in fact, I expect them to annoy some of my 
readers. Nevertheless, this may be my only opportunity to publish what I believe are the most 
important insights from my graduate career without the burden of co-authors to appease. The fact that 
my perspective seems so frequently to diverge from that of my colleagues may suggest that I am a 




Table of Contents 
 
Abstract ........................................................................................................................................................... ii 
Acknowledgments ......................................................................................................................................... iii 
Preamble......................................................................................................................................................... v 
List of Tables ................................................................................................................................................. vii 
List of Figures ................................................................................................................................................ vii 
Introduction .................................................................................................................................................... 1 
Chapter I:  Evaluating Clonal Expansion of HIV-infected Cells ...................................................................... 3 
Abstract ...................................................................................................................................................... 3 
Author Summary ........................................................................................................................................ 3 
Introduction ............................................................................................................................................... 4 
Results ........................................................................................................................................................ 6 
Discussion ................................................................................................................................................ 23 
Methods.................................................................................................................................................... 26 
Acknowledgments ................................................................................................................................... 27 
Supplementary Material .......................................................................................................................... 28 
Chapter II: A Quantitative Basis for the Clinical Success of Dolutegravir ................................................... 33 
Abstract .................................................................................................................................................... 33 
Introduction ............................................................................................................................................. 33 
Results and Discussion ............................................................................................................................ 35 
Methods.................................................................................................................................................... 43 
Discussion ..................................................................................................................................................... 45 
Clonal expansion in the latent HIV reservoir .......................................................................................... 45 
Quantifying the efficacy of antiretroviral therapy .................................................................................. 46 
References .................................................................................................................................................... 49 




List of Tables 
 
Table 1 ............................................................................................................................................................. 7 
Table 2 ........................................................................................................................................................... 18 
Table 3 ........................................................................................................................................................... 28 
 
 
List of Figures 
 
Figure 1 ........................................................................................................................................................... 9 
Figure 2 ......................................................................................................................................................... 14 
Figure 3 ......................................................................................................................................................... 17 
Figure 4 ......................................................................................................................................................... 20 
Figure 5 ......................................................................................................................................................... 29 
Figure 6 ......................................................................................................................................................... 30 
Figure 7 ......................................................................................................................................................... 31 
Figure 8 ......................................................................................................................................................... 32 
Figure 9 ......................................................................................................................................................... 36 
Figure 10 ....................................................................................................................................................... 39 






The fantastically rapid discovery, development, and approval of effective antiretroviral therapy (ART) 
for the treatment of HIV may be one of the greatest accomplishments ever achieved by medical science. 
Likewise, in the words of the World Health Organization, “the global health response to HIV represents 
one of the greatest public health feats of recent times.” The rate of new HIV infections and the 
frequency of HIV-related deaths worldwide have been decreasing for over a decade, while the number 
of infected people with access to treatment continues to rise [1]. However, the national and 
international medical communities foster no illusions that the HIV epidemic is under control. 
 
In 2014, over one million people worldwide died from causes related to HIV infection. The same year, 
two million more people were infected with the virus, which is the etiological agent responsible for the 
immunodeficiency disease known as AIDS. In 2014, zero people living with HIV were cured of their 
infection. The math is simple, but the implications are profound; the number of people worldwide living 
with HIV infection increased by almost one million in 2014 [1]. 
 
At the beginning of the HIV/AIDS epidemic, the most urgent and important task at hand was the 
management of people being infected with HIV and dying from AIDS. In recent years, thanks in large 
part to enormous strides in HIV treatment, this focus has broadened to encompass a new, expanding 
population in need of resources and attention, the population of people living with HIV. 
 
I know of four ways that the scientific and medical establishments can contribute to the global 
response against HIV: 
 
1. A continued public health effort to bring HIV testing, treatment, and prevention to affected 
communities. 
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2. The development of new antiretroviral drugs with novel mechanisms of action and/or 
improved toxicity profiles, decay rates, or price points. 
3. The development of a vaccine (or functional vaccine) to prevent new infections in high-risk 
populations. 
4. The development of a cure (or functional cure) to reduce the number of infected persons and 
at least partially alleviate the need for antiretroviral drugs. 
 
The first of these four can be achieved with strategies and technologies that already exist, although it 
may be expedited by the development of newer, better tools. The latter three goals require novel 
scientific innovation. The two chapters of this dissertation describe two different projects intended to 
contribute to the second and fourth goals in the above list. While the work presented here will almost 
certainly have zero impact on the lives of HIV-infected people or their communities, it nevertheless 








In HIV-infected individuals receiving suppressive antiretroviral therapy, the virus persists indefinitely in 
a reservoir of latently infected cells. The proliferation of these cells may contribute to the stability of the 
reservoir and thus to the lifelong persistence of HIV-1 in infected individuals. Because the HIV-1 
replication process is highly error-prone, the detection of identical viral genomes in distinct host cells 
provides evidence for the clonal expansion of infected cells. We evaluated alignments of unique, near-
full-length HIV-1 sequences to determine the relationship between clonality in a short region and 
clonality in the full genome. Although it is common to amplify and sequence short, subgenomic regions 
of the viral genome for phylogenetic analysis, we show that sequence identity of these amplicons does 
not guarantee clonality across the full viral genome. We show that although longer amplicons capture 
more diversity, no subgenomic region can recapitulate the diversity of full viral genomes. 
Consequently, some identical subgenomic amplicons should be expected even from the analysis of 
completely unique viral genomes, and the presence of identical amplicons alone is not proof of clonally 
expanded HIV-1. We present a method for evaluating evidence of clonal expansion in the context of 




Although antiretroviral therapy effectively blocks HIV-1 replication, the virus persists indefinitely in a 
reservoir of latently infected cells. This reservoir is a major barrier to HIV-1 cure. Recent studies have 
identified the proliferation of latently infected cells as a mechanism that may contribute to the lifelong 
persistence of HIV-1. In contrast with cellular proliferation, viral replication is highly error-prone; 
therefore, the detection of identical viral genomes in distinct host cells provides evidence that those 
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cells are the progeny of an infected cell that underwent clonal expansion. For this reason, the accurate 
and reliable identification of identical HIV-1 genomes derived from distinct cells is critical for 
understanding HIV-1 persistence and advancing cure research. Studies of HIV-1 clonal expansion often 
present clonality of short, subgenomic sequences as evidence for the clonality of full viral genomes. In 
this study, we quantified the relationship between sequence identity in short regions and sequence 
identity of near-full-length genomes to demonstrate that no subgenomic region completely captures 
the diversity of the full viral genome. Consequently, identical subgenomic sequences are not proof of 
identical full-length HIV-1 genomes. In the context of these findings, we developed a method to 




The HIV-1 virion carries two copies of a 9.7 kb RNA viral genome, which is reverse transcribed to DNA 
and integrated into the genome of a host cell during infection. Although combination antiretroviral 
therapy (ART) can suppress HIV-1 plasma viremia indefinitely to a level below the clinical limit of 
detection, the virus persists for decades in a latent reservoir composed of resting memory CD4+ T cells 
carrying integrated viral genomes, known as proviruses [2-5]. The development, composition, and 
plasticity of this latent reservoir, which presents a major barrier to the cure of HIV-1 infection, are all 
active areas of investigation [6,7]. 
 
An emerging body of research identifies the proliferation of latently infected CD4+ T cells as a possible 
mechanism for the persistence—and perhaps expansion—of the latent reservoir. Because viral 
replication is a low-fidelity process, expansion of the reservoir through cellular proliferation can be 
distinguished from expansion through de novo infection events by the presence of identical HIV-1 
genomes with identical sites of integration into the host cell genome in distinct cells [8-10]. 
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In part due to the substantial diversity of HIV-1 even within a single infected individual, generating full-
length sequences of individual proviruses can be prohibitively expensive and labor intensive. Instead, it 
is common to sequence short PCR amplicons covering less than 3000 base pairs [8,9,11-19]. While these 
smaller, subgenomic amplicons contain sufficient sequence information to inform phylogenetic 
analysis, they do not capture the total diversity–in this case, defined as the proportion of non-clonal 
sequences—present in full-length viral genomes from the same sample. On the contrary, the sequence 
diversity in a subgenomic region is best understood as a minimum estimate of the total sequence 
diversity in the sample analyzed. Without comparing full-length HIV-1 genomes, it is impossible to 
determine whether two proviruses with identical sequence over a subgenomic amplicon are also 
identical over the remainder of the viral genome. 
 
This inherent overestimation of viral clonality when comparing short, subgenomic sequences is of 
critical importance in the investigation of clonal expansion of latently infected cells as a mechanism of 
HIV-1 persistence. A number of studies have identified identical viral sequences in independent 
samples from a single subject [8,9,14,18-21]. These identical sequences may reflect the expansion of 
latently infected CD4+ T cells in vivo. However, when the identical sequences analyzed cover only a 
short fragment of the viral genome, they may also represent distinct infection events with viral 
genomes that happen to differ only in areas of the genome that were not analyzed. This distinction 
underscores the importance of understanding the relationship between the sequence diversity in 
subgenomic PCR amplicons and that of full viral genomes. 
 
The goal of this study was to identify which short PCR amplicons—if any—capture the total diversity of 
full-length genomes in a sample. We analyzed near-full-length HIV-1 sequences available from previous 
studies; importantly, we specifically characterized intra-subject diversity. We considered how length, 
genomic position, and sample type contribute to the likelihood that a given subgenomic amplicon will 
include enough information to differentiate unique, full-length HIV-1 sequences. Given these findings, 
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we characterized and evaluated eight PCR primer sets used in previously published studies of HIV-1 
diversity for their ability to differentiate full-length viral sequences. We showed that subgenomic 
sequences are contextualized by the primer set used to generate them, and we present here a strategy 




Data sets and processing. We analyzed data sets containing between 5 and 121 (mean=20.7, median=9) 
unique, near-full-length HIV -1 sequences from a total of 31 subjects. None of the sequences analyzed 
cover the 5’ LTR, and all sequences are fully characterized at a minimum from positions 2000 through 
8000 of the HXB2 reference genome. These sequences represent five different sample types: 1) proviral 
DNA from the resting CD4+ T cells of subjects who initiated suppressive ART during acute HIV-1 
infection, designated “Acute treated – DNA”; 2) proviral DNA from the resting CD4+ T cells of subjects 
who initiated suppressive ART during unspecified stages of chronic HIV-1 infection, designated “Chronic 
treated – DNA”; 3) proviral DNA isolated from quantitative viral outgrowth assay (VOA) [22] wells 
negative for p24 antigen, representing resting CD4+ T cells that were not induced to produce 
replication-competent virus after stimulation with phytohemagglutinin, designated “VOA – DNA”; 4) 
genomic viral RNA isolated from the plasma of viremic subjects over a series of longitudinal time points, 
designated “Longitudinal – RNA”; and 5) genomic viral RNA isolated from the plasma of subjects during 
acute HIV-1 infection, designated “Acute – RNA.”  The data sets were aligned to the HXB2 reference HIV-
1 genome and processed to remove repeat sequences. Sequences were characterized as repeats if they 
were identical or differed only at ambiguously sequenced positions for all nucleotides sequenced. Thus, 
every full-genome sequence is unique in the alignments analyzed below. Details about sequence data 
sets and their sources are shown in Table 1 and Table 3. We have shown that our results are not 
sensitive to the specific alignments; that is, the results are equivalent for different but equally probable 
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 Table 1. Sources and characteristics of sequence alignments analyzed to generate clonal prediction scores. 
 
 





Acute treated – DNA 
DNA from resting CD4+ T cells of 
subjects treated during acute infection 
Bruner et al., manuscript under 
revision [29] 
- 6 7-14 
Chronic treated – 
DNA 
DNA from resting CD4+ T cells of 
subjects treated during chronic 
infection 
Bruner et al., manuscript under 
revision [29] 
- 5 8-13 
VOA – DNA 
DNA from p24 antigen-negative 
quantitative viral outgrowth assay [22] 
culture wells 
Ho et al., 2013, Cell. [23] 24243014 5 6-12 
Longitudinal – RNA 
Plasma RNA from 2-10 longitudinal 
samples per subject 
Herbeck et al., 2011, J. Virol. [16] 21593162 6 28-121 
Acute – RNA 
Plasma RNA collected during acute 
infection  
Salazar-Gonzalez et al., 2009, J. 
Exp. Med. [15] 
19487424 9 5-14 
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alignments of the same sequences (Figure 5). For this study, only alignments including at least five 
unique, full-length HIV-1 genome sequences from the same individual were considered. 
 
Because our goal was to characterize intra-subject diversity, we analyzed the alignments from each 
subject individually. Figure 1a shows a schematic of our analytic procedure. We considered a series of 
hypothetical primer pairs defining subgenomic PCR amplicons. Each of these primer sets was 
evaluated against each subject sequence alignment. We assumed that a sequence could be amplified 
by a primer set if the sequence aligned to the HXB2 reference genome without any gaps in either primer 
site. 
 
For each sequence alignment, we considered the amplicons that would be produced by a PCR with a 
given hypothetical primer set, discarding the sequences that would not be amplified by that primer set 
due to insertions or deletions overlapping the primer binding sites. We chose to consider only PCR-
amplifiable sequences to maximize the practical value of our metric for the analysis of sequence data 
sets generated using PCR-based protocols. We defined the clonal prediction score (CPS) of the primer 
set as the number of unique amplicons produced, divided by the total number of amplicons produced, 
and multiplied by 100 (Figure 1a). In words, the CPS of a primer set with respect to an alignment is 
defined as the percentage of sequences in the alignment that would be correctly identified as unique 
using only the sequence region amplified by those primers. Each full genome in these alignments is 
unique, and primer sets that produce a unique amplicon for every amplifiable sequence in the 
alignment have a CPS of 100. 
 
These parameters define a maximal CPS of 100 and a minimum possible CPS of 100/N, where N is the 
number of amplified sequences. When a primer set will not amplify any of the sequences in an 
alignment, the CPS is undefined for that primer set with respect to that alignment. Undefined CPS 
values are excluded from the figures described below. Importantly, the precision of the CPS is limited 
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Figure 1. Clonal prediction scores of 1 kb amplicons spanning the HIV-1 genome. (a) Schematic of 
algorithm to calculate clonal prediction score (CPS), which quantifies the proportion of unique 
sequences in an alignment that are correctly identified as unique using the amplicons produced by a 
specific primer set. (b) CPS of 1 kb-wide amplicons spanning the HIV-1 genome for six Acute treated – 
DNA subjects. (c) CPS of 1 kb-wide amplicons spanning the HIV-1 genome, averaged over all subjects in 
five different sample categories (Table 1). (d) Overlay of the five plots in part c. Schematics of the HIV-1 
genome are aligned to the charts in parts b through d to highlight viral gene locations. The amplicons in 
parts b through d are defined with reference to the HXB2 genome.  
 
 10 
by the number of sequences amplified by a primer set. For example, a primer set that correctly 
distinguishes 5 of 5 amplicons would have the same perfect CPS = 100 as a primer set that correctly 
distinguishes 100 of 100 amplicons. If a new unique sequence were added to the alignment and 
incorrectly identified as clonal, the CPS values in these two cases would change to 83 and 99, 
respectively. For this reason, the empirically perfect CPS = 100 may be more precisely described as CPS 
> 100*N/(N+1). This example emphasizes why alignments containing more sequences lead to greater 
precision in CPS values. For clarity, we have plotted maximal CPS values at CPS = 100 in the figures 
described below. 
 
Substantial variation in CPS among subjects. To investigate how CPS varies across the HIV-1 genome 
and across infected individuals, we calculated CPS values for hypothetical 1 kb amplicons spanning the 
HIV-1 genome at 10 bp intervals. These amplicons were defined by hypothetical 10 bp forward and 
reverse primers, and we have shown that the results of the following analysis are not sensitive to the 
choice of primer length (Figure 6). While the amplicons defined by these hypothetical primers have a 
length of 1 kb in the HXB2 reference genome, they may have different lengths in sequences containing 
insertions or deletions between the primer sites. Along with sequence differences, length 
polymorphisms can be used to differentiate unique sequences. 
 
The results of this analysis for six Acute treated – DNA samples (Table 1) are shown in Figure 1b. There 
was substantial variation among subjects, suggesting that a primer set optimized to differentiate 
sequences in one sample may not be optimal in another sample from a different subject. For subject 
2453, almost every 1 kb amplicon contained sufficient variation to differentiate all amplified sequences, 
but the other five subjects had CPS values below 100 for amplicons spanning large portions of the 
genome. For subject 2521, less than one percent of all possible 1 kb amplicons had a perfect CPS of 100. 
That is, almost every 1 kb amplicon would incorrectly classify unique genomic sequences from subject 
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2521 as identical. There is no relationship between these patterns and the number of sequences 
analyzed for each subject (Figure 7 and Table 3). 
 
Plots of CPS across the genome for individual Chronic treated – DNA, VOA – DNA, Longitudinal – RNA, 
and Acute – RNA samples (Table 1) are shown in Figure 7. The perfect CPS of 100 is much more common 
for proviral DNA than for plasma RNA; in Chronic treated – DNA and VOA – DNA samples, more than half 
of subjects had perfect CPS values for every 1 kb amplicon across the viral genome. These perfect CPS 
values are often found at locations in the genome where one or more sequences in the alignment 
contain deletions and cannot be amplified. In these cases, the total number of sequences detected by a 
primer set (the denominator in the CPS equation) is lower, and there are fewer amplicons to be 
differentiated. Although alignments containing only a few sequences do not lead to bias or inaccuracy 
in the CPS, the precision of the CPS calculation is correlated with the number of sequences in the 
alignment being analyzed. In the compilation of our data set, we chose to include only subjects for 
whom at least five unique, near-full-length sequences had been characterized, but the precision of 
these results would be improved by the collection and inclusion of more sequences per subject. 
 
The dramatic variation in CPS among different subjects is seen in all sample types assayed except 
Longitudinal – RNA (Figure 7). For Longitudinal – RNA samples, CPS is consistent between subjects and 
across the viral genome. This result reflects the high diversity of the HIV-1 quasispecies during chronic 
infection. 
 
Lack of genomic hotspots for CPS across sample types. To determine whether optimized primer sets for 
the identification of clonal HIV-1 sequences should be located in specific regions of the viral genome, 
we plotted the CPS for hypothetical 1 kb amplicons spanning the HIV-1 genome, averaged over all of 
the subjects within each sample group (Figure 1c). The top plot in Figure 1c shows the average of the six 
plots in Figure 1b, and the other plots in Figure 1c show averages of the plots in Figure 7. Figure 1d is an 
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overlay of the five plots in Figure 1c. The purpose of these averaged scores was to determine whether 
any region of the viral genome yields consistently higher or lower CPS than other regions across 
different subjects or sample types. 
 
CPS values averaged over several subjects are relatively consistent across the viral genome for all five 
sample types evaluated. In the Acute treated – DNA and Chronic treated – DNA samples, CPS values 
appear slightly higher for the 5’ half of the genome than for the 3’ half. In contrast, the CPS for VOA – 
DNA samples is highest at the 3’ end of the genome. Importantly, these general trends are not 
representative of individual subjects, e.g., Acute treated – DNA subject 3693 has a perfect 100 CPS only 
for amplicons toward the 3’ end of the viral genome (Figure 1b). 
 
The Acute – RNA samples stand out as having lower CPS values across the viral genome than the other 
sample types (Figure 1d), indicating that the sequences in these alignments differ at relatively few 
places in the genome. This finding is consistent with the biological characteristics of the Acute – RNA 
sample type; these sequences contain low genetic diversity because they represent plasma collected 
during acute HIV-1 infection, before the viral quasispecies has expanded and developed the sequence 
diversity characteristic of chronic infection. In most individuals, HIV-1 infection is initiated by a single 
transmitted founder virus that expands into a diverse quasispecies over the course of untreated 
infection [23,24]. 
 
Importantly, these results show that there is no optimal region of the genome best suited for 
differentiating unique sequences in a subject- or sample type-independent manner.  
 
Effect of amplicon length on CPS. To determine the effect of amplicon length on CPS, we calculated the 
CPS for hypothetical amplicons of different lengths spanning the HXB2 genome. We summarized the 
analysis of all amplicons of a given length in three ways, by taking the average, median, and minimum 
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CPS over all amplicons of that length across the genome (Figure 2a). For example, all of the points 
plotted in the top chart from Figure 1b are averaged together to yield the subject 2286, 1000 bp data 
point in the Acute treated – DNA Average CPS plot in Figure 2a. Individual results for the 31 subjects are 
grouped by sample type. 
 
For every subject, regardless of sample type, longer amplicons yield higher CPS. This is unsurprising, as 
a longer amplicon should be more likely than a short amplicon to contain sequence diversity. However, 
the precise relationship between amplicon length and CPS varies dramatically by sample type. In 
proviral DNA samples, CPS increases with amplicon length but varies among subjects. For very short 
amplicons between 100 bp and 500 bp, average and median CPS can range from about 40 to a perfect 
100. For very large amplicons of 6 kb, the average CPS is greater than 80 and the median CPS is 100 for 
almost every proviral DNA sample. Again, there is no correlation between CPS and the number of 
amplicons in a sequence alignment (Figure 2 and Table 3). 
 
In DNA from subjects treated during chronic infection, the relationship between amplicon length and 
CPS is similar for three of five subjects. CPS values are high for the three Chronic treated – DNA samples 
that cluster together in Figure 2; all three subjects have a perfect CPS of 100 across the viral genome for 
amplicons as short as 1 kb. Subject CP03 is believed to have initiated therapy early in chronic infection, 
which may explain the similarity of that sample to the Acute treated – DNA samples. Subject CP10 
illustrates an important limitation of any sequence-based analysis. Two of the sequences in the CP10 
alignment differ by a single nucleotide. These sequences likely represent identical genomes that differ 
because of an error generated during PCR, but they were considered to be unique for this analysis. 
Because the error rate of PCR using high-fidelity polymerases is of a much lower magnitude than HIV-1 
sequence diversity, our results overwhelmingly reflect true viral diversity (rather than technical 
diversity) except in this exceptional case of PCR error in identical genomes. 
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Figure 2. Relationship between amplicon length and CPS. Summary statistics describing all 
amplicons of a given length, spanning the HXB2 reference genome at 10 bp intervals. Amplicons with 
undefined CPS were not included in these summary statistic calculations. (a) Average, median, and 
minimum of the CPS values for every amplicon of a specified length spanning the viral genome. 
Summary statistics are shown for each subject and grouped by sample type. (b) Proportion of all of the 
amplicons of a specified length that have CPS values above 80. 
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In plasma RNA samples, the relationship between amplicon length and CPS is direct and consistent 
across subjects. Unlike with the proviral DNA samples, the average and median CPS for plasma RNA can 
be lower than 20 for 100 bp amplicons. These low CPS values indicate alignments with many detectable 
sequences but insufficient sequence diversity to distinguish them using small amplicons. 
 
The relationship between amplicon length and CPS is direct and linear for Longitudinal – RNA samples. 
There is much less inter-subject variation in this relationship for Longitudinal – RNA than for any of the 
other sample types. Importantly, even the minimum CPS increases predictably with amplicon length 
for these samples. For all Longitudinal – RNA samples, the average CPS is greater than 95 for 2 kb 
amplicons, and even the minimum CPS for a 2 kb amplicon is greater than 90. This contrasts with the 
other sample types, where average CPS increases predictably with amplicon length but minimum CPS 
is variable. 
 
Figure 2a shows that most short PCR amplicons are limited in their capacity to distinguish unique HIV-1 
genomes, and that the goal of a single short amplicon with a perfect CPS of 100 in a variety of subjects 
and sample types is unattainable. Instead, we evaluated how many amplicons achieve high—but not 
necessarily perfect—CPS values. Figure 2b shows the proportion of amplicons of a given length with 
CPS > 80. The relationship between amplicon length and the frequency of amplicons with CPS > 80 is 
largely consistent with the results shown in Figure 2a but emphasizes the inter-subject differences in 
CPS patterns. 
 
Variation in PCR coverage with sample type and amplicon length. Importantly, CPS is undefined for a 
primer set that will not amplify any of the sequences in a given alignment. The summary statistics in 
Figure 2 describe only the primer sets with defined CPS for each subject. In other words, the CPS values 
shown in Figure 2 represent only the primer sets for which at least one sequence in the alignment is 
detectable. We calculated PCR coverage, or the fraction of sequences in each alignment that would be 
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detectable by PCR, averaged over all amplicons of a given length between HXB2 coordinates 2000 and 
8000 (Figure 3). We chose this region because it is fully characterized for every sequence in our data set, 
and so the data in Figure 3 reflect the presence of internal deletions in the sequences rather than 
missing sequence data. As described above, we considered amplicons defined by hypothetical primer 
sets spanning the region at 10 bp intervals.  
 
The PCR coverage reflects the overall percentage of the viral genome lost to internal deletions in each 
sample. This value is consistent across subjects in plasma RNA samples (Figure 3), for all of which the 
proportion of detectable amplicons approaches 100%, especially with very large 6 kb amplicons. 
Plasma RNA represents viral genomes capable of producing all of the viral proteins necessary to 
generate a functional virion and therefore does not contain large internal deletions. In contrast, 
proviral DNA samples are much less likely to be detected by PCR because of the high frequency of large 
internal deletions in archived proviral genomes [25]. There is substantial variation in PCR coverage for 
proviral DNA samples among different subjects and across sample types. On average, Acute treated – 
DNA sample sequences are more likely to be detected by PCR than Chronic treated – DNA or VOA – DNA 
sample sequences. 
 
The results shown in Figure 3 have implications for primer design independent of CPS. In proviral DNA 
samples, the results of PCR-based analyses may vary dramatically with the choice of primers because 
different sequences in the sample can be intact or deleted in different regions of the viral genome; bias 
may be introduced by the specific selection of only the sequences that happen to be intact in a 
particular region. 
 
CPS of previously published amplicons. We calculated the CPS for eight primer sets used in published 
studies of HIV-1 diversity, evolution, and clonal expansion (Table 2) with respect to the sequence 
alignments in our data set. The results, averaged over all subjects for each sample type, are presented 
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Figure 3. Relationship between amplicon length and PCR coverage. Percentage of sequences in 
each alignment that would be detectable by PCR, averaged over all amplicons of a specified length 
spanning HXB2 positions 2000 through 8000 at 10 bp intervals. Results are shown for 31 subjects and 
grouped by sample type (Table 1). 
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Table 2. Amplicons from published studies of HIV diversity, evolution, and clonal expansion. 
 







F primer R primer 
env 1 
Evering et al., 
2012, PLoS 
Pathog. [17] 
22319447 2948 5956 – 8903 TTAGGCATCTCCTATGGCAGGAAGAAG GTCTCGAGATACTGCTCCCACCC 
p6-gag-pro 
Palmer et al., 
2005, J. Clin. 
Microbiol. [13] 
15635002 1565 1870 – 3434 GAGTTTTGGCTGAAGCAATGAGCC TTAGTGGTACTACTTCTGTTAGTGTT 
pol 1 
Bailey et al., 
2006, J. Virol. [14] 
16775332 664 2598 – 3261 AYGGCCCAARAGTYAAAC TTATCAGGATGGAGYTCA 
env 2 
Delwart et al., 
1993, Science 
[11] 
8235655 667 7001 – 7667 CTGTTAAATGGCAGTCTAGC CACTTCTCCAATTGTCCCTCA 
pro 
Bailey et al., 
2006, J. Virol. [14] 
16775332 537 2056 – 2592 TGAAAGATTGTACTGAGAGACAGG CCTGGCTTTAATTTTACTGGTACAG 
env 3 
Bailey et al., 
2006, J. Virol. [14] 
16775332 471 1059 – 7529 ACAATGCTAAAACCATAATAGT CATACATTGCTTTTCCTACT 
pol 2 
Wagner et al., 
2013, J. Virol. [18] 





Palmer et al., 
2003, J. Clin. 
Microbiol. [12] 
14532178 79 1298 – 1376 CATGTTTTCAGCATTATCAGAAGGA TGCTTGATGTCCCCCCACT 
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in Figure 4a. Consistent with the results in Figure 2, larger amplicons typically have higher CPS values, 
and this relationship is most distinct in plasma samples. Importantly, in most of the samples shown, 
none of the published primer sets have a perfect CPS of 100. Consequently, in any analysis of sequences 
derived using these primers, some unique full-length genomes will be misrepresented as identical 
amplicons. 
 
Using CPS to quantify false-positive clonality. The analysis of subgenomic amplicons to characterize HIV-
1 genomes cannot provide definitive evidence of clonality in a sample, even when identical sequences 
are detected. The CPS for a primer set indicates how much false-positive clonality is found by that 
primer set in alignments of unique genomes. Thus the CPS for alignments of unique genomes can be 
understood as an estimate of the background signal expected when using a given primer set to 
evaluate clonality. We used the CPS of published primer sets to estimate the presence or absence of 
true clonality in published phylogenetic trees. This analysis is described in detail in the Methods 
section. 
 
In short, we plotted the relationship between the total number of sequences analyzed and the number 
of unique sequences detected (Figures 4b and 4c). The CPS of a primer set is represented as a black line 
on these plots, and red dashed lines indicate the CPS plus or minus one standard deviation. We then 
plotted phylogenetic trees from six previously published studies [8,9,14,17-19] as points on the same 
axes. Each plot in Figures 4b and 4c shows a different primer set, and each point represents a single 
phylogenetic tree generated using that primer set. Figure 4b shows results for trees composed of 
proviral DNA samples, and Figure 4c shows trees composed of plasma RNA samples. Trees containing 
both RNA and DNA were separated and evaluated individually; these trees are represented by separate 
points in Figure 4b and Figure 4c. The distance between the lines (CPS, background signal estimate) 
and the points (sample data) demonstrate the amount of true clonality likely to be present in a sample.
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Figure 4. CPS of previously published amplicons. (a) CPS for each of the primer sets listed in Table 2, 
averaged over all subjects within each sample type (Table 1). (b and c) Evaluation of previously 
published phylogenetic trees in the context of the CPS of the primer sets used to generate those trees. 
Part b shows proviral DNA samples and part c shows plasma RNA samples. Black diagonal lines show 
the relationship between the number of sequences collected and the number expected to be unique for 
each primer set listed in Table 2, as an estimate of the background signal level (assuming no clonality); 
the slopes of these lines are equal to the CPS values in part a divided by 100. The dotted red lines were 
calculated as the black lines plus or minus one standard deviation in CPS. Each plotted point indicates 
the actual number of total sequences and unique sequences present in a previously published 
phylogenetic tree. Phylogenetic trees containing both proviral DNA and plasma RNA sequences were 
counted separately for the two sequence types  and plotted separately in parts b and c. Points plotted 
far below the black line (green-shaded region) indicate trees with more clonality than would be 
expected by chance from a sample of unique HIV-1 genomes. *References in which hypermutated 




Importantly, the black lines in Figures 4b and 4c do not lie along the x=y axis. For every primer set 
defining a subgenomic amplicon, even in a sample composed entirely of unique HIV-1 genomes, some 
false-positive clonal amplicons are likely to be detected, causing the slope of the black line to deviate 
from 1. The expected number of false positive identical amplicons (y-axis) increases proportionally with 
the total number of amplicons sequenced (x-axis). 
 
Points that lie on the black lines are consistent with the null hypothesis that there are no clonally 
expanded HIV-1 genomes in the sample. Points that fall below the black line suggest clonal expansion, 
i.e., the presence of more identical amplicons than would be expected in a sample composed of unique 
viral genomes. We did not see evidence of points plotted well above the black line, which would have 
indicated greater sequence diversity than was present in the alignments used to generate this model. 
This observation serves as validation of the data sets used to train our model. 
 
Studies in which trees do not include hypermutated sequences are marked with an asterisk. 
Hypermutated sequences are easily distinguishable even using short amplicons because of their 
tremendous diversity (Figure 8). For this reason, the removal of hypermutated or otherwise defective 
sequences from an alignment will artificially deflate the ratio of unique sequences to total sequences 
detected. In other words, for trees that have been curated to remove hypermutated sequences, the true 
location of the points plotted in Figures 4b and 4c is expected to fall closer to the black line. Due to the 
mechanisms of APOBEC-mediated hypermutation and HIV-1 reverse transcription, the rate of 
hypermutation is not constant across the viral genome25,26; the relationship between CPS and genome 
location in hypermutated sequences is shown in Figure 8b. 
 
The analysis shown in Figure 4 provides a method for evaluating both primer sets and sequence data. A 
primer set with high CPS and minimal variation in CPS across samples provides the most powerful 
background estimate to enable the confident interpretation of sequence data. And regardless of the 
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primers used to generate sequences, phylogenetic trees and sequence alignments can only be 





In this study, we defined the CPS as a metric for how well a subgenomic amplicon differentiates unique 
HIV-1 genomes. We calculated CPS values for hypothetical amplicons of varying sizes across the HIV-1 
genome to investigate the contribution of size and location to the capacity of an amplicon to 
distinguish unique genomes. Finally, we calculated the CPS values for commonly used primer sets and 
used them to estimate the background level of clonality in phylogenetic trees generated with those 
primer sets. 
 
The primary goal of this study was to identify PCR amplicon(s) best suited to differentiate unique, full-
length HIV-1 genomes. We found compelling evidence that no single, subgenomic amplicon will be 
sufficient to distinguish HIV-1 genomes across a variety of sample types or subjects. However, we 
evaluated eight previously published primer sets and found that of those, a 1.5 kb amplicon in the p6-
gag-pro region seems to be the best compromise between coverage, practicality, and CPS, a metric 
which describes the capacity of an amplicon to correctly identify unique sequences as unique. 
 
We also identified a variety of best practices to maximize the validity of future studies of HIV-1 clonality 
in any sample type. Most importantly, researchers should always emphasize which region is being 
sequenced and explicitly consider the CPS of the amplicon(s) used. This context is essential for 
evaluating claims of clonal expansion, as it provides an estimate of the expected background signal 
against which sequencing results should be compared. We recommend against highlighting identical 
amplicons as evidence of full-genome clonality without comparing those results to an appropriate 
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background estimate, and we emphasize that the only way to definitively demonstrate clonal 
expansion is to corroborate results with full-genome and integration site sequencing.  
 
Importantly, all of the analyses presented here assume that the individual amplicons sequenced were 
collected independently using methods specifically designed for single-genome sequencing. Many 
studies are confounded by PCR resampling [28]; all sequences analyzed using the methods described 
here should be collected independently. 
 
Furthermore, although some analyses call for curated sequence data, every full, uncurated data set 
should be made available. Phylogenetic trees presented to highlight clonally expanded populations 
should not be curated to remove replication-incompetent sequences. As described above, the removal 
of hypermutated sequences from a data set artificially inflates the proportion of clonal sequences in 
that data set. When evaluating alignments or trees against the background CPS of the amplicon 
sequenced, it is necessary to analyze every sequence collected. 
 
To aid researchers in the analysis of new data sets with different amplicons than those described here, 
we have published a Web tool available at http://silicianolab.johnshopkins.edu/cps. This tool computes 
the CPS for user-specified primer sets and performs a comparison with user-entered values to 
characterize phylogenetic trees or alignments of amplicons in the context of appropriate background 
signal estimates. 
 
Whether using this CPS analysis or any other method, it is impossible to conclusively prove or disprove 
the clonality of full-length viral genomes using only the sequence of a subgenomic amplicon. However, 
because information about the region amplified is available, it is essential to consider this context 
when interpreting data. These implications are no less relevant for phylogenetic studies in fields 
beyond HIV persistence; whenever the results and interpretation of a phylogenetic analysis may be 
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impacted by the choice of amplicon sequenced, it is critical to consider that impact explicitly in the 
evaluation and presentation of data. This CPS analysis is intended not as a definitive arbiter of full-
sequence clonality but as a tool to quantify the context provided by primer location and inform the 
interpretation of sequence data.  
 
Some important limitations of this study suggest additional considerations for future research. We have 
considered amplicon sequences on a binary scale; either sequences are correctly identified as unique, 
or they are not. We have not considered the distribution of sequence clonality. For example, in an 
amplicon alignment with twenty total sequences and only ten sequences correctly identified as unique, 
we did not distinguish between cases where the ten clonal sequences are identical to each other and 
cases where they represent duplicates of several other sequences. The case where all clonal sequences 
are identical may or may not be more likely to represent full-genome clonality; the quantification of 
that likelihood is beyond the scope of this study. 
 
In this study, we took advantage of sequence alignments representing a variety of sample types. 
Importantly, the results of our analyses often varied dramatically, especially between plasma RNA HIV-
1 genomes, which are typically intact, and proviral DNA genomes, which often contain large internal 
deletions. Although the CPS of a primer set is clearly correlated across sample types, the implications of 
our analysis for different sample types than those evaluated in this study are imprecise. We have also 
shown that even within a sample type, the variation in CPS among subjects can be extreme. 
Additionally, especially in the case of proviral DNA sequences containing deletions, the methods used 
to identify full-length genomic HIV-1 sequences in previous studies may have been more efficient for 
some sequences than for others. Any bias in the nature of the sequences used to define our CPS model 
may be reflected in our results. For these reasons, the model presented here and any future 
calculations of CPS would benefit from the inclusion of more full-length or near-full-length HIV-1 
genome sequences and sample types collected in the future. 
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In summary, identical HIV-1 sequence fragments must be validated to demonstrate full-genome 
clonality conclusively. This validation can be achieved in a variety of ways. When technical constraints 
permit, additional regions of the genome can be sequenced. To demonstrate the clonality of proviral 
DNA sequences, the best validation is to sequence the associated integration site. Unvalidated 
sequences may be described as “identical throughout the region sequenced” but without further 
corroboration should not be described as clonally expanded. The web tool available at 
http://silicianolab.johnshopkins.edu/cps can be used to calculate CPS for the evaluation of new data or 




Online tool. The online tool to calculate CPS can be found at http://silicianolab.johnshopkins.edu/cps. 
The tool is written in JavaScript, and the code is accessible at https://github.com/gitliver/HIVCPS. All 
sequences used for CPS analysis are available from GenBank. 
 
CPS plots. The CPS values in Figure 4a are similar across all three DNA sample types. To calculate the 
expected CPS of a given primer set as used to characterize a proviral DNA sample, we averaged the CPS 
of that primer set for the three DNA sample types. To calculate the expected CPS of a given primer set 
used to characterize a plasma RNA sample, we used the average CPS from the Longitudinal – RNA 
samples (Figure 4a). We chose not to include the Acute – RNA samples in this average because plasma 
virus from acutely infected individuals contains much less diversity than any other sample type, and its 
relevance to the analysis of other samples is minimal. The appearance of the Acute – RNA sample type 
as an outlier is evident in Figures 1, 2, and 4a. 
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For each primer set in Table 2, we used the average CPS values for proviral DNA and plasma RNA 
samples to calculate the proportion of false-positive clonal sequences that should be expected from 
sequencing subgenomic HIV-1 RNA or DNA amplicons. The relationship between the total number of 
amplicons sequenced and the expected number of correctly identified unique amplicons detected for 
each primer set is plotted as a black line in Figures 4b (proviral DNA) and 4c (plasma RNA). The slope of 
this line is the CPS divided by 100. The dashed red lines give a confidence interval representing one 
standard deviation in CPS values. 
 
We counted the total number of sequences and the number of unique sequences in 53 different 
phylogenetic trees from six previously published studies [8,9,14,17-19]. The color and shape of the 




Many thanks to Oliver Elliott for adapting the CPS calculator algorithm into an online tool. The authors 
would also like to thank Dr. Christine Durand, Dr. Andrew Redd, Dr. Stuart Ray, and Dr. Daniel 
Rosenbloom for helpful discussions and advice. 
 
The work presented in this chapter is in press as of this writing [30]. 
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Supplementary Material 




Figure 5. Clonal prediction scores are equivalent for different, equally probable alignments of the 
same sequences. The Longitudinal – RNA sample sequences were aligned to the HXB2 reference 
genome in two different but equally probable alignments. CPS values were calculated for 1 kb 
amplicons spanning the viral genome at 10 bp intervals (see Figure 1). Parts a and b show that CPS 





Figure 6. Clonal prediction scores of hypothetical amplicons are insensitive to the choice of 
hypothetical primer length. CPS values were calculated for 1 kb amplicons spanning the viral genome 
at 10 bp intervals. These amplicons were defined by hypothetical primers based on the HXB2 reference 
genome. The choice of hypothetical primer length used to define the amplicons characterized in Figure 









Figure 7. Clonal prediction scores of 1 kb amplicons spanning the HIV-1 genome for individual 
subject sequence alignments. CPS of 1 kb-wide amplicons spanning the HIV-1 genome for all subjects 
not shown in Figure 1b. The average of these plots over all subjects within each sample type are shown 





Figure 8. Clonal prediction scores of hypothetical short amplicons used to characterize 
hypermutated or non-hypermutated sequences. CPS values were calculated separately for the 
hypermutated and non-hypermutated sequences from the same subjects. Results are shown for four 
subjects with 4 unique hypermutated sequences and 3 unique non-hypermutated sequences. (a) 
Average CPS values over all hypothetical amplicons of a given length spanning the viral genome are 
shown for the hypermutated-only and non-hypermutated-only alignments (see Figure 2). CPS values are 
higher for hypermutated sequences, indicating that hypermutated sequences are much easier to 
distinguish than non-hypermutated sequences using amplicons as small as 100 bp. (b) CPS of 200 bp-wide 
amplicons spanning the HIV-1 genome (see Figure 1) with hypermutated and non-hypermutated 
sequences evaluated separately. The top plot emphasizes locations in the genome where even 









The clinical success of antiretroviral drugs against HIV-1 is highly correlated with the results of in vitro 
assays that quantify drug efficacy. The only exceptions are the first-generation integrase strand transfer 
inhibitors (InSTIs), which are under-valued by in vitro models. The second-generation InSTI dolutegravir 
(DTG), which has been in clinical use since late 2013, has not been described using these analyses. To 
develop a quantitative understanding of its efficacy and mechanism of action, we evaluated DTG using 
quantitative in vitro infectivity assays. We measured the efficacy of DTG alone and in combination with 
nucleoside reverse transcriptase inhibitors (NRTIs), and we measured the ability of DTG to inhibit both 
wild-type HIV-1 and virus containing InSTI resistance mutations. The results of our analysis were 
consistent with the clinical success of DTG. We demonstrated a high genetic barrier to DTG resistance; 
favorable interactions between DTG and NRTIs; and a mechanism of action for DTG consistent with that 
of the successful first-generation InSTI raltegravir. We showed that the recommended DTG-based 
regimens for treatment of HIV-1 are sufficiently efficacious to inhibit all viral replication at clinical 
concentrations, suggesting that this second-generation InSTI is not under-valued by our quantitative in 




Two years after its approval, the second-generation HIV-1 integrase strand transfer inhibitor (InSTI) 
dolutegravir (DTG) has demonstrated not only efficacy [31-35] but also cost-effectiveness [36] and a 
high barrier to resistance in vivo [37,38]. Despite the remarkable clinical success of DTG, its 
pharmacodynamic properties in combination with other antiretroviral drugs and against HIV-1 
containing InSTI resistance mutations have not been evaluated comprehensively using quantitative in 
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vitro models. Despite underestimating the efficacy of first-generation InSTIs, the results of these models 
correlate closely with the clinical success of antiretroviral drug regimens used to treat HIV-1 [39,40]. 
 
A quantitative understanding of antiretroviral efficacy allows for a more thorough theoretical 
evaluation of antiretroviral therapy than is feasible in a clinical setting. The extensive variety of 
available drugs, along with their typically combinatorial usage, yields far more possible drug 
combinations than can be practically tested individually in the clinic. Moreover, determination of the 
parameters that define a dose-response relationship allows for the extrapolation of drug efficacy at 
very high, clinical concentrations, which are beyond the detection range of in vitro assays. Quantitative 
analyses describing the efficacies of antiretroviral drugs can be used to predict more efficacious drug 
regimens, both for wide clinical use and for salvage therapy in the case of multi-drug resistant virus. 
 
We used an in vitro infectivity assay and subsequent quantitative modeling to evaluate the efficacy of 
DTG in combination with nucleoside analog reverse transcriptase inhibitor (NRTI) pairs 
abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/FTC). To quantify the genetic barrier 
to DTG resistance, we measured pharmacodynamic properties of DTG against HIV-1 containing InSTI 
resistance mutations. We also hypothesized that the excellent clinical efficacy of dolutegravir might be 
due to inhibition of integration as well as late steps in the HIV-1 life cycle, which are not measured by 
standard infectivity assays [39,40]. This hypothesis is suggested by the finding that allosteric integrase 
inhibitors (ALLINIs) affect HIV-1 maturation as well as integration [41-45]. The first-generation InSTI 
raltegravir has not shown activity at posttranslational steps of the HIV-1 life cycle [41-43], but the 
efficacy of dolutegravir against these steps has not been assessed. 
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Results and Discussion 
 
DTG interacts favorably with NRTIs. We measured the dose-response relationships for DTG, ABC, 3TC, 
TDF, and FTC separately and in combination using a phenotypic assay that quantifies the number of 
single-round infection events inhibited by a given concentration of one or more drugs (see Methods). 
The median effect curves plotted in Figure 9A show the log of drug concentration plotted against a 
logarithmic metric of efficacy; curves are linear for drugs that act without cooperativity [39]. The three-
drug combinations shown (ABC/3TC/DTG and TDF/FTC/DTG) are DHHS-recommended treatment 
regimens for individuals initiating antiretroviral therapy [46]. 
 
We used the Loewe additivity [47] and Bliss independence [48] models of combined drug efficacy to 
calculate the expected efficacies of drug combinations given the experimentally determined efficacies 
of the individual component drugs. Loewe additivity assumes that drugs act through the same target; 
Bliss independence describes drugs that inhibit distinct targets. At clinically relevant concentrations, 
the Loewe model predicts lower combined efficacy than the Bliss model. Importantly, in practice, 
antiretroviral drugs do not interact exclusively according to either model; understanding how drugs 
interact with reference to these models allows the prediction of combined efficacy at concentrations 
beyond the limits of in vitro assays, including clinical concentrations [40]. 
 
In Figure 9A, the interactions between drugs can be quantified by comparing the drug combination 
dose-response curves (gray) to the Loewe (red dashed) and Bliss (blue dashed) model predictions. 
Degree of independence (DI), a scale defined by the Loewe and Bliss models, describes these 
interactions quantitatively. Some antiretroviral drug combinations exhibit an intermediate DI with 
efficacy between the Loewe and Bliss predictions, and other combinations exhibit synergy, defined as a 
higher combined efficacy than that predicted by the Bliss model [40]. Pie charts in Figure 9A show DI 
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Figure 9. Efficacy of DTG and NRTIs alone and in combination. (A) Median effect curves, with 
normalized logarithmic drug concentration (x-axis) plotted against a logarithmic measure of efficacy (y-
axis). fa is the fraction of infection events affected, i.e. inhibited, by the drug(s) at the stated 
concentration; fu is the fraction of infection events unaffected by the drug(s), and fu = 1 – fa. Solid lines 
show experimentally determined dose-response relationships, with the color distinguishing the drug(s) 
used. The gray “combination” line refers to the combination specified in the label above each chart. 
Dashed lines show the Loewe additivity (red) and Bliss independence (blue) model predictions for 
combined efficacy given the experimentally determined efficacies of the individual drugs. Drug 
concentrations were chosen so that all drugs would have similar efficacy at the reference concentration 
D0: [D0,DTG]=52.7nM; [D0,ABC]=558nM; [D0,3TC]=434nM; [D0,TDF]=354nM; [D0,FTC]=110nM. Error bars show the 
standard deviation of six biological replicates. Inset pie charts show degree of independence (DI) 
calculated for two- and three-drug combinations, according to the color scale in the legend, based on 
the empirically determined dose-response relationships. Each pie slice shows the results from a 
different biological replicate. (B) Average IIP over a 24-hour dosing period for individual drugs and their 





values for DTG combined with NRTI(s). There is some variation among donors; overall, DTG/ABC/3TC 
interact according to the Bliss model, and DTG/TDF/FTC interact synergistically. 
 
DTG-based regimens have sufficient efficacy to suppress viremia. Instantaneous inhibitory potential (IIP) 
quantifies the number of logs by which HIV-1 infection is reduced by a drug or drug combination [39]. 
IIP is a function of the drug concentration(s) as well as the slope and IC50 parameters that describe 
dose-response curve(s), and the IIP for a drug combination depends on the DI of the combination. 
Regimens with a combined average IIP>5 throughout the dosing interval typically are able to control 
HIV-1 infection completely in a clinical context [40]. Figure 9B shows average IIP over the dosing 
interval for individual drugs and the three-drug combinations DTG/ABC/3TC and DTG/TDF/FTC, as well 
as the two-drug combination DTG/3TC, which has shown some clinical efficacy [49]. For all three 
combinations, the average IIP over the dosing interval is >5, consistent with complete viral suppression 
in a clinical context. 
 
DTG has a high genetic barrier to resistance. We tested the ability of DTG to inhibit HIV-1 containing 
previously characterized InSTI resistance mutations. Figure 10A shows median effect dose-response 
curves for DTG against a panel of drug-resistant viruses. The high genetic barrier to DTG resistance is 
evident from the modest effect of resistance mutations on the IC50 of DTG (Figure10); the impact of 
these resistance mutations on first-generation InSTI IC50—and of canonical drug resistance mutations 
for other antiretroviral drug classes—is often orders of magnitude higher [50]. Additionally, although 
drug resistance mutations have been shown to dramatically impact the slope of the dose-response 
curves for antiretroviral drugs from other classes, the slopes of first-generation InSTIs are relatively 
constant even in the context of drug-resistant virus [50]. DTG recapitulates this phenotype, as all of the 
median effect curves in Figure 10A have similar slopes (Figure 10C). 
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Figure 10. Pharmacodynamic properties of DTG against HIV-1 containing InSTI resistance 
mutations. (A) Median effect dose-response curves showing DTG efficacy against various drug-resistant 
viruses. For this plot, the reference concentration [DTG0]=50nM. (B) Fold change in IC50 of DTG dose-
response curves for drug-resistant viruses as compared to wild-type virus. (C) Fractional change in 
slope of DTG dose-response curves for drug-resistant viruses as compared to wild-type virus. (D) IIP of 
DTG at the maximal clinical concentration(Cmax) against wild-type and drug-resistant viruses. IIP is a 
function of the IC50, the dose-response curve slope, and the drug concentration. (E) Fractional change in 
IIP of DTG at Cmax against drug-resistant viruses as compared to wild-type viruses. (F) Replication 
capacity of wild-type and drug-resistant viruses, measured as the ratio of maximal infection levels in 
culture for drug-resistant and wild-type virus. (G) Selective advantage of each virus at Cmax. Selective 
advantage is defined as the replication capacity of the drug-resistant virus multiplied by the ratio of the 
infectivity for the drug-resistant virus to the infectivity for the wild-type virus, where infectivity is 
defined as the proportion of infection events unaffected by the drug, or fu [50].  
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The combined impact of drug resistance mutations on DTG efficacy can be demonstrated by IIP, which 
takes into account the effect of resistance mutations on dose-response curve slope and IC50. The impact 
of resistance mutations on the IIP of DTG at the maximum clinical concentration (Cmax) is shown in 
Figures 10D and 10E. Single point mutations have minimal impact on the IIP of DTG, and the change in 
IIP due to combinations of two point mutations is of comparable magnitude to that of single point 
mutations in first-generation InSTIs and other drug classes [50].  
 
The ability of a drug-resistant virus to replicate in the presence of the drug is impacted both by the 
magnitude of resistance conferred by a mutation and by the fitness cost of that mutation. The impact 
on viral fitness of the InSTI resistance mutations tested is shown in Figure 10F. The selective advantage 
of each viral strain, which takes into account both the magnitude of resistance and the fitness cost of 
resistance, is shown in Figure 10G. The virus with the greatest replicative advantage over wild-type is 
G140S/Q148R, which combines a ten-fold shift in IC50 with only a moderate fitness cost. The G140S 
mutation, which confers no resistance on its own, has been shown to act as a compensatory mutation 
for other InSTI resistance mutants [51]. 
 
DTG does not act late in the HIV-1 life cycle. To determine whether the success of DTG is due in part to 
activity during late steps of the HIV-1 life cycle (virus assembly, release, and maturation), we designed a 
modified phenotypic assay (Figure 11A, Methods). Maximally activated CD4+ T cells were infected with 
two different viral inoculums, which contained equal concentrations of drug and virus; the only 
difference between the conditions was whether the virus was produced and consequently underwent 
the posttranslational steps of the HIV-1 life cycle in the presence (Inoculum A) or absence (Inoculum B) 
of integrase inhibitors. We used the first-generation InSTI raltegravir as a negative control for late life 
cycle activity [41-43] and the ALLINI BI-D, which has been shown to inhibit virion maturation, as a 
positive control [41-45]. 
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Figure 11. Activity of integrase inhibitors in early and late portions of HIV-1 life cycle. (A) 
Schematic of inoculum preparation for the life cycle assay, which differentiates between virus activity 
early and late in the HIV-1 life cycle. Virus is produced either in the presence or the absence of a drug 
and then drug/virus combinations are used to infect primary CD4+ T cells. (B) Median effect dose-
response curves for BI-D (left), raltegravir (center), and dolutegravir (right). Open circles represent data 
points below the detection range of the assay. The top row shows the individual results from five 
healthy blood donors; error bars represent the standard deviation of three technical replicates. The 
bottom row shows the results averaged over all five biological replicates in each condition, with error 
bars representing one standard deviation. Due to the design of this assay, drugs are at 20-fold higher 
concentration during the virus preparation step than during the infection step; reference 
concentrations refer to the drug concentration during virus production. Reference concentrations for 
these plots are: [D0,DTG]=45nM; [D0,RAL]=97nM; [D0,BI-D]=50 nM. 
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The difference between virus produced in the presence versus the absence of BI-D is dramatic, with a 
>2.5-log difference in inhibition at the highest concentration tested (Figure 11B, left). Although 
inhibition of infection by BI-D present during virion maturation (Inoculum A) was readily detected, 
infection was not inhibited by BI-D that was combined with virus after the completion of maturation 
(Inoculum B) at any concentration tested. This is consistent with a previous report that the IC50 of BI-D 
as an integrase inhibitor is 13-fold higher than the IC50 of BI-D as a maturation inhibitor [44]. In sharp 
contrast to the results obtained with BI-D, there was no difference in infectivity between virus produced 
in the presence or the absence of raltegravir, with <0.2-log difference in inhibition between Inoculums A 
and B at all concentrations tested (Figure 11A, center). These contrasting results for raltegravir and BI-D 
demonstrate the ability of our assay to measure drug effects on late steps in the HIV-1 life cycle 
separately from effects on integration.  
 
Figure 11A (right) shows median effect dose-response curves for DTG. There is no difference in 
infectivity between virus produced in the presence of DTG and virus produced without drug. High dose-
response curve slopes and nonlinear dose-response curves are indicative of antiretroviral drugs that 
act at multiple steps of the HIV-1 life cycle [52], and high slopes correspond with high in vitro efficacy at 
clinical concentrations [39,40,52]. Both Inoculums A and B have DTG dose-response curves with slopes 
of 1.3 ± 0.1, consistently higher than the slope of ~1 previously reported for first-generation InSTIs [39]. 
 
Conclusions. The overwhelming clinical success and rapidly increasing popularity of DTG suggest the 
importance of extending the quantitative framework describing antiretroviral therapy [39,40,50,53] to 
include this second-generation InSTI. DTG shares many pharmacodynamic features with first-
generation InSTIs, including efficacy restricted to the early part of the HIV-1 life cycle and a linear 
median-effect dose-response curve with a slope that remains consistent despite resistance mutations. 
However, DTG has a higher dose-response curve slope than first-generation InSTIs, which translates to 
higher predicted efficacy at clinical concentrations. Importantly, this quantitative model, which has 
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been shown to undervalue first-generation InSTIs, predicts sufficient efficacy at clinical concentrations 
to completely suppress viremia for both ABC/3TC/DTG and TDF/FTC/DTG, consistent with the clinical 
success of these two regimens. This high efficacy is due to both the steeper slope of DTG and the 




Phenotypic assay. The phenotypic assay used to quantify DTG efficacy alone and in combination against 
WT and mutant HIV-1 has been previously described [29,30,50,54]. Briefly, maximally activated primary 
CD4+ T lymphoblasts from healthy blood donors were spinoculated with the single-round fluorescent 
reporter virus NL4-3 ΔEnv-EGFP in the presence of varying concentrations of drug(s), and the 
proportion of infected cells was quantified by FACS.  
 
Life cycle assay. 293T cells were transfected using Lipofectamine 2000 (Life Technologies) with a 
plasmid carrying the proviral clone NL4-3 with EGFP in place of the env gene and a separate plasmid 
carrying the IIIB env gene to produce single-round fluorescent reporter virus. A second flask of 293T 
cells was mock transfected. 6-7 hours after transfection, the cells were trypsinized and transferred to 
96-well plates in media comprised of 45% RPMI, 5% FBS, 50% human serum (Gemini), and 12mM 
HEPES. Integrase inhibitors were added to half of the wells to produce the following conditions: 1) 
transfected 293T cells incubated with drug, 2) transfected 293T cells incubated without drug, 3) mock 
transfected 293T cells incubated with drug, and 4) mock transfected 293T cells incubated without drug 
(Figure 11A). 
 
After a 48-hour incubation, supernatant was recovered, centrifuged briefly to remove cellular debris, 
and transferred to a fresh plate. The conditions described above produced supernatant containing the 
following:  1) virus matured in the presence of drug, 2) virus matured in the absence of drug, 3) drug 
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without virus, and 4) neither virus nor drug. Supernatants 1 and 4 were combined at equal volumes to 
yield Inoculum A, virus produced in the presence of drug. Supernatants 2 and 3 were combined at equal 
volumes to yield Inoculum B, virus and drug that had been incubated separately. Both combinations 
were used to infect PHA-activated primary CD4+ T lymphoblasts by spinoculation at 1200 x g and 37°C 
for two hours. Infection was measured after 72 hours by EGFP fluorescence on a FACSCalibur (BD). 
 
Analysis. Previously published values were used for the slope, IC50, Cmax, and half-life parameters of ABC, 
3TC, TDF, FTC [40], as well as the Cmax and half-life of DTG [55]. The IIP for each drug combination 
according to the Loewe, Bliss, or empirical estimate of combined drug efficacy was calculated for every 
minute over a 24-hour dosing interval assuming rapid drug penetration. Average IIP over the dosing 
interval was reported as the average of these values. The average IIP calculation was performed using a 




Clonal expansion in the latent HIV reservoir 
 
A full explication of my opinions on HIV latency research far exceeds the scope of this dissertation. 
Briefly, I am all but convinced that strategies intended to diminish the size of the latent HIV reservoir 
cannot and will not ever form the basis of a successful HIV cure. Among other considerations, this 
opinion is based in a quantitative understanding of data that I think are typically interpreted 
qualitatively.  My greatest hope for the HIV cure field is that it manages to prove me wrong as swiftly as 
possible. 
 
Toward that end, researchers in the field are studying the composition, establishment, and variation of 
the HIV reservoir in resting CD4+ T cells. The analysis presented in Chapter I of this dissertation was 
intended to encourage reflection, attention to detail, and quantitative thinking, all of which should 
improve the quality and applicability of any biomedical research regardless of its ultimate practical 
use. 
 
I initially developed the clonal prediction score metric to be a mirror, not a tool. My goal was to 
emphasize to researchers the obvious but infrequently acknowledged limitations of their assays and, 
ideally, encourage them to consider those limitations in the interpretation of results. We designed the 
online CPS calculator to facilitate that process, but it has severe limitations of its own. Most critically 
and least surprisingly, there just is not enough full-length HIV sequence data available to support the 
robust and precise calculation of CPS, especially for a variety of samples and sample types. The 
limitations of my resources are reflected in the deficiencies of my finished product, but I hope that the 
CPS calculator—much like the analysis of short, identical HIV sequence regions—can still provide 
practically useful, if technically inconclusive, data. 
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If the CPS calculator is never used, but some scientist somewhere is inspired by its theoretical basis to 
present results alongside an explicit discussion of their technical limitations, then I will be satisfied with 
the impact of the work presented here. 
 
Quantifying the efficacy of antiretroviral therapy 
 
To put it bluntly, the “context of related work in the literature”1 for this project is as follows:  The 
Siliciano lab published several papers establishing a quantitative framework to explain the efficacy of 
antiretroviral drugs. Other groups evidently saw these publications and read them; I have discussed 
their content with members of the federal government, other academic research institutions, and even 
pharmaceutical companies. Nevertheless, the work was met with a glaring lack of follow-up research or 
practical implementation by any other group, including those who so readily praised it. The ultimate  
implication of these premises is impossible to ignore; notwithstanding their pretty compliments, no 
one (myself and my advisor awkwardly excluded) was interested in seeing more work in this vein. 
 
Knowing this, I chose to evaluate dolutegravir with the quantitative model anyway. While I really am 
pleased with the quality of the data I produced, the most realistic and perhaps rational future direction 
for this project is a dusty corner of Bernard Forscher’s metaphorical brickyard2. Given its inauspicious 
foundation, I see little advantage to be gained by incorporating my brick into a wall. 
 
While considering the limitations and future directions of projects including the one presented in 
Chapter II of this dissertation, I started to conceive of a fundamentally different but potentially 
informative framework for the quantitative evaluation of antiretroviral drugs. Much to the chagrin of 
                                                     
1 Biomedical Engineering PhD Guidelines, Johns Hopkins School of Medicine, June 2015. 
2 Chaos in the Brickyard, Bernard K Forscher, Science, 1963. 
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my advisor, I am sure, this new model relies on the understanding  that suppressive antiretroviral 
therapy may not entirely prevent new HIV infection events in the body of a treated patient. Rather, it 
may be the case that suppressive antiretroviral therapy prevents new viral lineages of enough 
generations to evolve multi-drug resistance—an important distinction which I will explain in more detail 
below. 
 
To the extent that I am forced by lack of an alternative to believe published scientific results, I see no 
way to dispute the following: 
 
1. The notable historical absence of drug resistance in patients adhering to suppressive 
antiretroviral treatment is far too robust to believe that substantial viral replication could take 
place in the presence of therapy, even if said replication were largely restricted to anatomical 
sanctuaries. 
2. The consistent clinical evidence of increases in 2LTR circles upon raltegravir intensification of 
suppressive regimens is far too robust to believe that all viral replication is inhibited even by 
the most efficacious combination therapy.3 
 
I am likewise convinced that these two statements are perfectly reconcilable. “When you have 
eliminated the impossible, whatever remains, however improbable, must be the truth.”4  
 
In the face of these data, I am forced to conclude that some ongoing HIV replication takes place in the 
face of suppressive antiretroviral therapy, but that replication is insufficient to produce multi-drug 
resistant virus. My hypothesis relies on the vanishingly low probability of HIV evolving high-level 
                                                     
3 Even if these findings are entirely restricted to patients receiving protease inhibitor-based regimens, a rebuttal based on that 
fact must assume that protease inhibitor-based regimens are not fully suppressive throughout the dosing period, and therefore 
that ongoing replication should be expected at least in patients treated with protease inhibitors. 
4 The Sign of the Four, Arthur Conan Doyle, Lippincott’s Monthly Magazine, 1890. 
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resistance to every component of a combination drug regimen during a single round of replication. 
Instead, the evolution of multi-drug resistance is much more likely to comprise the sequential 
accumulation of resistance mutations across several viral generations. A virus replicating with a small 
but nonzero reproductive ratio (R0) might produce new infection events consistently without ever 
achieving the long viral lineages necessary to accumulate multiple resistance mutations. In this way, 
the ongoing replication implied by treatment intensification studies is compatible with the long-term 
viral suppression of treated individuals. 
 
I think that an instructive framework for evaluating the efficacy of antiretroviral therapy might quantify 
the distribution of viral lineage lengths in the presence of drug(s), rather than the single-round 
inhibition of viral infection. Such a model would expect some ongoing replication in the presence of 
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